Jingwu Z Zang

Title: The Innovations of Jingwu Z Zang

Introduction

Jingwu Z Zang is a notable inventor based in Missouri City, TX (US). He has made significant contributions to the field of immunology, particularly in the development of T cell therapies. With a total of 2 patents, his work focuses on understanding and treating T cell associated diseases.

Latest Patents

Zang's latest patents include "Isolation and identification of cross-reactive T cells" and "Autologous T-cell vaccines materials and methods." The first patent discusses the recognition of cross-reactive T cells that can identify both MBP and HHV-6 peptides. This discovery suggests that these T cells have a less stringent requirement for the flanking residues of the peptides compared to mono-specific T cells. The association between HHV-6 and autoreactive immune responses to MBP indicates that these cross-reactive T cells, along with antiviral agents, may play a role in preventing or treating multiple sclerosis. The second patent relates to improved autologous T cell vaccines and methods for their production, aimed at treating diseases such as multiple sclerosis and rheumatoid arthritis.

Career Highlights

Throughout his career, Zang has worked with various organizations, including Opexa Pharmaceuticals, Inc. and Opexa Therapeutics, Inc. His experience in these companies has allowed him to advance his research and contribute to the development of innovative therapies.

Collaborations

Due to space constraints, the collaborations section has been omitted.

Conclusion

Jingwu Z Zang's work in the field of immunology and his innovative patents highlight his commitment to advancing medical science. His contributions have the potential to significantly impact the treatment of T cell associated diseases.